2021
Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair
Dow J, Krysztofiak A, Liu Y, Colon-Rios DA, Rogers FA, Glazer PM. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. Molecular Cancer Research 2021, 19: 2057-2067. PMID: 34535560, PMCID: PMC8642278, DOI: 10.1158/1541-7786.mcr-21-0456.Peer-Reviewed Original ResearchConceptsHistone deacetylase inhibitor vorinostatPatient-derived tumor xenograftsHomology-directed repairIsocitrate dehydrogenase 1/2 mutationsHistone deacetylase inhibitionIDH1 mutant cellsGreater cell deathHDACi treatmentInhibitor vorinostatTumor xenograftsDeacetylase inhibitionIDH1/2 mutationsPotential biomarkersSpecific cancersMutant cancersCancerCancer cellsDNA repair defectsMalignancyVorinostatDNA double-strand breaksGliomasHistone hypermethylationCell deathPARPi
2015
When defense becomes dangerous--transcription factor Nrf2 and cancer.
Krysztofiak A, Krajka-Kuźniak V. When defense becomes dangerous--transcription factor Nrf2 and cancer. Postępy Higieny I Medycyny Doświadczalnej 2015, 69: 140-52. PMID: 25614681.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTranscription factor Nrf2Factor Nrf2Significance of Nrf2Expression of genesProtein Keap1Upstream kinaseRole of Nrf2Activation of Nrf2Nrf2 phosphorylationConformational changesBiotransformation of drugsTreatment of cancerTherapeutic effectCytoprotective enzymesDrug resistanceNrf2Adverse effectsEnzymatic systemsPhase IICancerPotential carcinogensActivationKinaseGenesPhosphorylation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply